Amicus Therapeutics (FOLD) 11.61 $FOLD
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 65.98 (-1.52), HZNP: 22.77 (-0.30), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 7.50 (+0.13), MDT: 78.02 (+0.36), CLDX: 30.38 (-1.40), FOMX: 10.00 (+0.10), AMGN: 170.10 (+0.99), AET: 108.63 (+0.32), NKTR: 12.02 (+0.13), CELG: 128.50 (+3.17), HUM: 182.79 (+1.83), CANF: 5.30 (+0.24), ANTM: 158.38 (+1.06), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), GERN: 3.98 (-0.15), AZN: 72.70 (+1.80), CLLS: (), WCG: 93.72 (+0.61), FOLD: 11.61 (-0.85), REGN: 488.87 (+2.85), CUR: 2.42 (+0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT
RALY: 12.93 (+1.84), GMAN: 4.91 (+0.55), VTAE: 12.36 (+1.70), YOKU: 13.50 (-1.65), NVGN: 3.82 (-0.14), ONTX: 2.57 (-0.03), ISNS: 2.42 (-0.36), EAC: 4.63 (-0.71), ONE: 2.56 (-0.31), VTL: 24.86 (-2.51), VGGL: 1.64 (+0.19), CALA: 15.75 (+1.68), ENVI: 1.97 (+0.43), CTRP: 57.58 (+11.44), VBLT: 5.75 (+1.01), PRTA: 38.66 (+9.43), NXTD: 3.87 (+0.71), OGEN: 1.15 (-0.11), FOLD: 11.61 (-0.85), BGI: 1.35 (-0.03)
Amicus Therapeutics Has Returned 31.4% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Fri Mar 20, 9:23AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 weeks, Amicus Therapeutics has returned 31.44% as of today's recent price of $11.54.
FOLD: 11.61 (-0.85)
Critical Alerts For Twitter, Ctrip.com, Prothena, Amicus Therapeutics and Ryder Released By InvestorsObserver
PR Newswire - Fri Mar 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TWTR, CTRP, PRTA, FOLD and R.
R: 98.00 (+1.01), CTRP: 57.58 (+11.44), PRTA: 38.66 (+9.43), TWTR: 48.44 (+0.51), FOLD: 11.61 (-0.85)
Amicus spikes on filing plans
at Investor's Business Daily - Thu Mar 19, 6:09PM CDT
Shares of the small biotech company soared 33.3% to 12.46 after it said that it would file for accelerated approval of lead drug candidate migalastat, an oral treatment for Fabry disease, following positive meetings with FDA and EU regulators. Amicus...
FOLD: 11.61 (-0.85)
Amicus Therapeutics Set to Possibly Pullback After Yesterday's Rally of 33.26%
Comtex SmarTrend(R) - Thu Mar 19, 3:56PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $11.63 to a high of $13.20. Yesterday, the shares gained 33.3%, which took the trading range above the 3-day high of $9.95 on volume of 21.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 11.61 (-0.85)
Freeport-McMoRan and Guess are big market movers
AP - Thu Mar 19, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
VTSS: 5.34 (+0.03), RTRX: 22.34 (+0.17), MSCC: 36.34 (-0.34), KTWO: 22.39 (+0.44), FOLD: 11.61 (-0.85), NKTR: 12.02 (+0.13), ADBE: 77.36 (+0.22)
Amicus to seek Fabry disease drug approval
AP - Thu Mar 19, 11:46AM CDT
CRANBURY, N.J. (AP) — Amicus Therapeutics plans to file for accelerated approval of its experimental treatment for a rare, inherited disease following meetings with regulators in the U.S. and Europe.
FOLD: 11.61 (-0.85)
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Mar 19, 10:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the orphan drugmaker Amicus Therapeutics ...
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan
at The Street - Thu Mar 19, 10:04AM CDT
Amicus Therapeutics (FOLD) shares are up double digits after the company announced that it will seek approval for its Fabry disease treatment, migalastat, earlier than expected.
FOLD: 11.61 (-0.85)
Amicus Up As FDA, EU Green-light Quick Drug Filings
at Investor's Business Daily - Thu Mar 19, 10:03AM CDT
Small biotech Amicus Therapeutics (FOLD) jumped more than 30% Thursday after the company said it would file for accelerated approval of its lead drug candidate after positive meetings with the FDA and EU authorities. Amicus' drug migalastat would be...
INSM: 21.80 (-0.20), SRPT: 13.16 (-0.76), SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:16AM CDT
GES: 18.84 (-0.58), SYN: 2.59 (+0.06), SMLR: 4.65 (-0.12), SQM: 18.86 (+0.99), PWE: 1.51 (unch), RMGN: 1.45 (-0.01), CNDO: 3.90 (-0.31), CBMX: 2.07 (-0.03), NBG: 1.34 (+0.14), NQ: 3.74 (-0.15), CNCE: 14.76 (unch), FOLD: 11.61 (-0.85)
Amicus up 20% premarket on accelerated timelines for Europe and U.S. applications for migalastat
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:41AM CDT
SHPG: 253.64 (+3.07), PLX: 1.76 (-0.03), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Accelerates Approval Filing Plans for Rare Disease Drug
at The Street - Thu Mar 19, 6:41AM CDT
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA and FDA Meetings for Fabry Monotherapy
GlobeNewswire - Thu Mar 19, 5:00AM CDT
MAA Submission for Full Approval Planned in European Union - Company to Accelerate Submission Timeline for MAA Filing to 2Q15
FOLD: 11.61 (-0.85)
Scanning Biotech Equities -- Agenus, Amicus Therapeutics, Peregrine Pharma, Vanda Pharma, and Acorda Therapeutics
PR Newswire - Thu Mar 12, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 5.40 (-0.15), VNDA: 9.57 (-0.21), PPHM: 1.49 (-0.04), ACOR: 34.74 (-0.39), FOLD: 11.61 (-0.85)
Amicus Therapeutics Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 9:23AM CST
FOLD: 11.61 (-0.85)
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 8:08PM CST
FOLD: 11.61 (-0.85)
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 65.98 (-1.52), HZNP: 22.77 (-0.30), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 7.50 (+0.13), MDT: 78.02 (+0.36), CLDX: 30.38 (-1.40), FOMX: 10.00 (+0.10), AMGN: 170.10 (+0.99), AET: 108.63 (+0.32), NKTR: 12.02 (+0.13), CELG: 128.50 (+3.17), HUM: 182.79 (+1.83), CANF: 5.30 (+0.24), ANTM: 158.38 (+1.06), NVO: 49.53 (+1.33), GILD: 102.29 (+0.85), GERN: 3.98 (-0.15), AZN: 72.70 (+1.80), CLLS: (), WCG: 93.72 (+0.61), FOLD: 11.61 (-0.85), REGN: 488.87 (+2.85), CUR: 2.42 (+0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT
RALY: 12.93 (+1.84), GMAN: 4.91 (+0.55), VTAE: 12.36 (+1.70), YOKU: 13.50 (-1.65), NVGN: 3.82 (-0.14), ONTX: 2.57 (-0.03), ISNS: 2.42 (-0.36), EAC: 4.63 (-0.71), ONE: 2.56 (-0.31), VTL: 24.86 (-2.51), VGGL: 1.64 (+0.19), CALA: 15.75 (+1.68), ENVI: 1.97 (+0.43), CTRP: 57.58 (+11.44), VBLT: 5.75 (+1.01), PRTA: 38.66 (+9.43), NXTD: 3.87 (+0.71), OGEN: 1.15 (-0.11), FOLD: 11.61 (-0.85), BGI: 1.35 (-0.03)
Amicus Therapeutics Has Returned 31.4% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Fri Mar 20, 9:23AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 weeks, Amicus Therapeutics has returned 31.44% as of today's recent price of $11.54.
FOLD: 11.61 (-0.85)
Critical Alerts For Twitter, Ctrip.com, Prothena, Amicus Therapeutics and Ryder Released By InvestorsObserver
PR Newswire - Fri Mar 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TWTR, CTRP, PRTA, FOLD and R.
R: 98.00 (+1.01), CTRP: 57.58 (+11.44), PRTA: 38.66 (+9.43), TWTR: 48.44 (+0.51), FOLD: 11.61 (-0.85)
Amicus spikes on filing plans
at Investor's Business Daily - Thu Mar 19, 6:09PM CDT
Shares of the small biotech company soared 33.3% to 12.46 after it said that it would file for accelerated approval of lead drug candidate migalastat, an oral treatment for Fabry disease, following positive meetings with FDA and EU regulators. Amicus...
FOLD: 11.61 (-0.85)
Amicus Therapeutics Set to Possibly Pullback After Yesterday's Rally of 33.26%
Comtex SmarTrend(R) - Thu Mar 19, 3:56PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $11.63 to a high of $13.20. Yesterday, the shares gained 33.3%, which took the trading range above the 3-day high of $9.95 on volume of 21.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 11.61 (-0.85)
Freeport-McMoRan and Guess are big market movers
AP - Thu Mar 19, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
VTSS: 5.34 (+0.03), RTRX: 22.34 (+0.17), MSCC: 36.34 (-0.34), KTWO: 22.39 (+0.44), FOLD: 11.61 (-0.85), NKTR: 12.02 (+0.13), ADBE: 77.36 (+0.22)
Amicus to seek Fabry disease drug approval
AP - Thu Mar 19, 11:46AM CDT
CRANBURY, N.J. (AP) — Amicus Therapeutics plans to file for accelerated approval of its experimental treatment for a rare, inherited disease following meetings with regulators in the U.S. and Europe.
FOLD: 11.61 (-0.85)
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Mar 19, 10:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the orphan drugmaker Amicus Therapeutics ...
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan
at The Street - Thu Mar 19, 10:04AM CDT
Amicus Therapeutics (FOLD) shares are up double digits after the company announced that it will seek approval for its Fabry disease treatment, migalastat, earlier than expected.
FOLD: 11.61 (-0.85)
Amicus Up As FDA, EU Green-light Quick Drug Filings
at Investor's Business Daily - Thu Mar 19, 10:03AM CDT
Small biotech Amicus Therapeutics (FOLD) jumped more than 30% Thursday after the company said it would file for accelerated approval of its lead drug candidate after positive meetings with the FDA and EU authorities. Amicus' drug migalastat would be...
INSM: 21.80 (-0.20), SRPT: 13.16 (-0.76), SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:16AM CDT
GES: 18.84 (-0.58), SYN: 2.59 (+0.06), SMLR: 4.65 (-0.12), SQM: 18.86 (+0.99), PWE: 1.51 (unch), RMGN: 1.45 (-0.01), CNDO: 3.90 (-0.31), CBMX: 2.07 (-0.03), NBG: 1.34 (+0.14), NQ: 3.74 (-0.15), CNCE: 14.76 (unch), FOLD: 11.61 (-0.85)
Amicus up 20% premarket on accelerated timelines for Europe and U.S. applications for migalastat
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:41AM CDT
SHPG: 253.64 (+3.07), PLX: 1.76 (-0.03), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Accelerates Approval Filing Plans for Rare Disease Drug
at The Street - Thu Mar 19, 6:41AM CDT
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA and FDA Meetings for Fabry Monotherapy
GlobeNewswire - Thu Mar 19, 5:00AM CDT
MAA Submission for Full Approval Planned in European Union - Company to Accelerate Submission Timeline for MAA Filing to 2Q15
FOLD: 11.61 (-0.85)
Scanning Biotech Equities -- Agenus, Amicus Therapeutics, Peregrine Pharma, Vanda Pharma, and Acorda Therapeutics
PR Newswire - Thu Mar 12, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 5.40 (-0.15), VNDA: 9.57 (-0.21), PPHM: 1.49 (-0.04), ACOR: 34.74 (-0.39), FOLD: 11.61 (-0.85)
Amicus Therapeutics Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 9:23AM CST
FOLD: 11.61 (-0.85)
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 8:08PM CST
FOLD: 11.61 (-0.85)
